Biotech | August 09, 2021
Novavax and Serum Institute submits Emergency Use Authorisation of vaccine to regulatory agencies in India, Indonesia and the Philippines
Filing for WHO Emergency Use Authorisation this month
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Deal for 100 million doses with additional 100 million through 2023
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The first batch will be shipped to the Gamaleya Center for the quality control
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
Subscribe To Our Newsletter & Stay Updated
